Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart versus IVIg in adults with multifocal motor neuropathy
NL-OMON60365Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of empasiprubart in multifocal motor neuropathy (MMN) (2 arms), sponsored by argenx. Primary endpoint: Change from baseline in grip strength in the most affected hand at week 24. Started Sep 2025; status: active, not recruiting.
02
Drugs
empasiprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NL-OMON60365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60365.